(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of 53.88% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Ars Pharmaceuticals's revenue in 2025 is $97,122,000.On average, 4 Wall Street analysts forecast SPRY's revenue for 2025 to be $7,529,739,081, with the lowest SPRY revenue forecast at $5,453,799,042, and the highest SPRY revenue forecast at $9,259,574,531. On average, 4 Wall Street analysts forecast SPRY's revenue for 2026 to be $20,299,269,855, with the lowest SPRY revenue forecast at $12,476,068,654, and the highest SPRY revenue forecast at $24,397,230,688.
In 2027, SPRY is forecast to generate $35,208,186,629 in revenue, with the lowest revenue forecast at $30,794,862,052 and the highest revenue forecast at $37,763,114,205.